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ment. This PCR product was subcloned into the pBluescript 
vector (Stratagene) and sequenced. It was found to represent 
RNA molecules in which the normal exon IIIc 3 ' splice site 
had been used, but not the normal 5' splice site (Fig. 1C). A 
new 5' splice site is used, defining an intron whose 5f end 
maps 2 nt downstream from the Crouzon mutation studied.
We interpret these data as follows. In the normal gene, the 
IIIc exon uses two alternative 5' splice sites (Fig. 1C), with 
only very minor use being made of the upstream site. We 
cannot call the upstream site a cryptic site, as minor use of 
the upstream site is also made in splicing of pre-mRNA from 
the endogenous FGFR2 gene in HeLa cells (our unpublished 
work) and has also been described in chicken lung and brain 
(8). Analogous use of a corresponding internal 5' splice site 
has also been described in the IIIc exon of the mouse FGFR1 
gene (2). The Crouzon G to A transition makes the upstream 
site correspond more closely to the 5' splice site consensus 
sequence, and the splicing apparatus switches to use of the 
upstream 5' splice site. Our data show that the G to A transi­
tion in exon IIIc alone is sufficient to provoke the change of 
5' splice sites: no additional mutations in the flanking exons 
are needed.
The extracellular domain of the normal FGFR2 is com­
posed of 3 Ig domains (5). The third domain, encoded in part 
by the IIIc exon, is involved in ligand binding (5, 6). As a 
result of the change in 5' splice sites, the FGFR2 mRNA 
produced in Crouzon syndrome now codes for a receptor lack­
ing 17 amino acids of this domain. With this information in 
hand, it is possible to test the effect of FGFR2 signal trans­
duction of the Crouzon syndrome mutation. This should in 
turn add to our understanding of the disease.
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Bone morphogenetic protein-4 (BMP-4) is a member of the 
transforming growth factor-  ^(TGF-/3) superfamily and is in­
volved in morphogenesis and bone cell differentiation (2). Re­
combinant BMP-4 can induce ectopic cartilage and bone for­
mation when implanted subcutaneously or intramuscularly 
in rodents. This ectopic bone formation process resembles the 
process of bone formation during embryogenesis and fracture 
healing (10). A cosmid clone containing the complete human 
bone morphogenetic protein-4 gene (BMP4) was isolated (de­
tails to be published elsewhere) and used as a probe to deter­
mine the precise chromosomal localization of the human 
BMP4 gene. This cosmid clone was labeled with biotin-14- 
dATP and hybridized in situ to chromosomal preparations of 
metaphase cells as described previously (6). In 20 metaphase 
preparations, an intense and specific fluorescence signal 
(FITC) was detected on the q arm of chromosome 14. The 
DAPI-counterstained chromosomes were computer-con-
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FIG. 1. Flúorescence in situ hybridization of the BMP4-con­
taining cosmid to region q22-q23 of human chromosome 14. (A) 
Positively imaged chromosomes showing hybridization signal (ar­
rowhead) and (B) chromosome 14: morbid anatomy with localization 
of BMP4.
verted into GTG-like banding patterns (Fig. 1), allowing the 
regional localization of BMP4 within 14q22-q23. This result 
is in agreement with a previous mapping of the human BMP4 
gene to chromosome 14 (7). For this latter study a human— 
rodent somatic cell hybrid panel and a BMP-4 cDNA probe
were used, which did not allow a more detailed chromosomal 
sublocalization. The present fine localization of BMP4 to 
14q22-q23 makes BMP-4 a possible candidate gene for Holt- 
Oram syndrome (HOS). HOS is a heritable disorder of skele­
tal and cardiac development (5). The HOS phenotype is prob­
ably determined early in embryogenesis. This heterogeneous 
disorder (8) may be caused by several types of gene mutations 
or deletions on either chromosome 12q or 14q. Although one 
HOS locus has been localized to chromosome 12, other forms 
of HOS have also been described (1), which are not linked to 
chromosome 12 (6). In one case, a direct association has been 
established between HOS and a deletion of the 14q23-q24.2 
region (9), The BMP4 localization to 14q22-q23 shown here 
in combination with the putative role of BMP-4 in limb devel­
opment (3) and its distribution during development (4) sug­
gests that the disturbed development of skeleton and heart 
in some HOS patients may be due to a disturbed BMP4 ex­
pression or an altered gene product. However, such an associ­
ation of BMP4 with HOS still must be confirmed by genetic 
linkage and mutation analyses.
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